Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced participation in the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 2:55 p.m. ET. The management will engage in a fireside chat, showcasing the company’s commitment to addressing unmet medical needs through innovative biopharmaceuticals.

A live webcast will be available on Kiniksa’s website, with a replay accessible 48 hours after the event, ensuring broad outreach to investors and stakeholders.

News Market Reaction – KNSA

+9.46%

+9.46% Session move

In the trading session that priced this news, KNSA gained 9.46%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022 at 2:55 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST^®, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ® Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com

FAQ

What time is Kiniksa Pharmaceuticals' presentation at the Wedbush PacGrow Healthcare Conference?

Kiniksa Pharmaceuticals will participate in a fireside chat on August 9, 2022, at 2:55 p.m. Eastern Time.

Where can I watch the Kiniksa Pharmaceuticals conference presentation?

You can watch the live webcast of Kiniksa’s presentation on their Investors & Media section of their website.

Will there be a replay of Kiniksa Pharmaceuticals' presentation from the conference?

Yes, a replay of the presentation will be available on Kiniksa’s website approximately 48 hours after the event.

What does Kiniksa Pharmaceuticals focus on?

Kiniksa Pharmaceuticals focuses on discovering and developing therapeutic medicines for patients with significant unmet medical needs.

What products are in Kiniksa's portfolio?

Kiniksa's portfolio includes ARCALYST®, KPL-404, and mavrilimumab, which target various underserved conditions.